Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan;34(1):41–49. doi: 10.5732/cjc.014.10278

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Chinese Journal of Cancer

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.

PMC Copyright notice

Figure 1. — NER is a particularly important mechanism by which the cell can prevent unwanted mutations by removing the vast majority of DNA damage that is produced by platinum-based therapies such as trabectedin. The recognition of these distortions leads to the removal of a short single-strand DNA segment that includes the lesion, creating a single-strand gap in the DNA that is subsequently filled in by DNA polymerase by using the undamaged strand as a template. NER can be divided into two subpathways (global genomic NER and transcription-coupled NER), which differ only in their recognition of helix-distorting DNA damage (see the text for details). CSA, Cockayne syndrome A; XPE, xeroderma pigmentosum, complementation group E; HR23B, RAD23 yeast, homolog B; ERCC1, excision repair cross-complementation group 1; RPA, human replication protein; TFIIH, transcription factor II human; DDB, damaged DNA-binding protein; PCNA, proliferating cell nuclear antigen.